OXiGENE, Inc. (NASDAQ: OXGN, XSSE: OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced today that the Company has added two new members to its Board of Directors. The addition of Roy Hampton Fickling and William D. Schwieterman, M.D., as Directors brings the total number of OXiGENE Directors to nine.
